Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences

^{Published on 2012-09-04 04:46:51 - Market Wire}
 

Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences -- SAN DIEGO, Sept. 4, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about OREX

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]) today announced that management will present a company overview at four investor conferences during the first two weeks of September. These four corporate presentations will be webcast.

Friday, September 7^th at 8:30 a.m Eastern Time: NewsMakers in the Biotech Industry Conference in New York City

Monday, September 10^th at 11:15 a.m. Eastern Time: Rodman & Renshaw Annual Global Investment Conference in New York City

Wednesday, September 12^th at 10:55 a.m. Eastern Time: Morgan Stanley Global Healthcare Conference in New York City

Thursday, September 13^th at 1:45 p.m. London Time: Bank of America Merrill Lynch Global Healthcare Conference in London

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company's Web site at [ www.orexigen.com ]. A replay will be available for 14 days after each event.

Additionally, on Wednesday, September 5^th at 4:00 p.m. Eastern Time, Orexigen management will participate in a panel discussion at the Citi 7^th Annual Biotech Day event. This event will not be webcast.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.  The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at [ www.orexigen.com ].

SOURCE Orexigen Therapeutics, Inc.

RELATED LINKS
[ http://www.orexigen.com ]